Clinical Trial Update: Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum [Phase 2]

View source ↗

Summary

Phase II trial update for neoadjuvant FOLFOX4 and cetuximab in localized rectal adenocarcinoma has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• FOLFOX4 (Folinic acid (Leucovorin), Fluorouracil (5-FU), Oxaliplatin)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Rectal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-05-01